An experimental drug originally developed to combat cancer may offer a new approach to treating osteoporosis and managing weight gain in women after menopause, according to a recent study.
The drug, identified as CADD522, functions by blocking a protein crucial for the growth and spread of certain cancers. Researchers at the University of East Anglia observed that in post-menopausal mice, the treatment not only appeared to strengthen bones but also contributed to leaner body composition.
Osteoporosis affects a significant portion of women over 50, increasing vulnerability to fractures. Current treatments often come with side effects, safety concerns, or complex dosing regimens, making long-term adherence challenging.
"We have uncovered an entirely new way of tackling the disease," said lead researcher Dr. Darrell Green. "We found that a drug originally developed to stop cancer could help millions of women facing the twin challenge of fragile bones and midlife weight gain."
The research, published in the journal npj Drug Discovery, involved mice that underwent surgery to simulate menopausal hormonal changes. Over an eight-week treatment period with CADD522, these mice demonstrated notable improvements in bone health. Scans revealed an increase in bone volume and better preservation of the internal bone structure, vital for strength.
Blood tests indicated that CADD522 stimulated new bone growth without disrupting the natural bone remodeling process. This is a key distinction from many existing osteoporosis drugs that primarily focus on suppressing bone loss, which can lead to complications with prolonged use.
Unexpected Metabolic Benefits
Beyond bone health, the study noted significant metabolic effects. Mice treated with CADD522 weighed less than their untreated counterparts, despite consuming the same amount of food. They also exhibited reduced body fat and less fat accumulation within the bone marrow, a common occurrence after menopause that is linked to declining bone health.
Further analysis of brain tissue suggested that the drug might reverse certain menopause-related changes in fatty acids. Levels of beneficial omega-3 fatty acids, such as DHA, remained stable, and other lipid abnormalities shifted towards healthier patterns. While memory and cognitive function were not directly assessed, these findings raise questions about the drug's potential to address broader menopausal health issues.
Safety and Future Prospects
Safety evaluations in mice, rats, and dogs indicated that CADD522 could be administered orally and was well-tolerated. The drug also appeared to be metabolized more slowly in human tissue compared to rodents, potentially enhancing its efficacy in people.
"This is still in the early stages and has so far only been tested in animals, but we hope that the benefits will translate to humans to ultimately reduce fracture rates," Dr. Green stated. The research team hopes their work could pave the way for a new generation of osteoporosis treatments that address bone loss and some of the metabolic consequences of menopause.